Effectiveness in 2025–2026
- Hospitalization Protection: Updated vaccines reduced hospitalizations by ~55% among adults with COVID-like illness.
- Emergency Care Visits: Effectiveness against ED/urgent care visits was ~50%, showing strong real-world impact.
- Variant Adaptation: Omicron-adapted boosters provide superior protection compared to older monovalent doses.
Safety Profile
- Adverse Events: Serious side effects remain rare, with most reactions mild (fever, fatigue, injection-site pain).
- Long-term Data: Evidence shows sustained safety, though more research is needed for children, cancer patients, and immunocompromised groups.
WHO Guidance (2026)
- Routine Vaccination: Recommended for high-risk groups (elderly, immunocompromised, healthcare workers).
- Coadministration: COVID-19 vaccines can be safely given alongside influenza and other routine immunizations.
- Future Research: Focus on durability of protection, variant-specific boosters, and equity in global distribution.
